Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.

作者: Eiji Higashihara , Kikuo Nutahara , Masaya Oshi , Takatsugu Okegawa , Masao Higaki

DOI:

关键词:

摘要: Aim To assess whether zoledronic acid (ZOL) adds to the effect of combined androgen blockade (CAB) in patients with hormone-naive bone metastatic prostate cancer. Patients and methods were treated either a combination CAB (luteinizing hormone-releasing hormone agonist bicalutamide) ZOL (CAB-Z group) or CAB-alone (historical control patients, CAB-C group). was injected intravenously at 4 mg every weeks. One hundred five 100 among 205 enrolled assigned CAB-Z group group, respectively. The time prostate-specific antigen (PSA) failure compared that group. primary end-point study time-to-PSA failure. Results PSA serum N-telopeptide type I collagen (NTx) levels examined before treatment 3 months after treatment. occurred 42 (40.0%) 48 (48.0%) biochemical recurrence-free rate significantly lower (p=0.004, by log-rank test). categorical biopsy Gleason score pre-treatment NTx shown be independent predictors failure-free survival (p=0.040, p=0.005 p=0.026, respectively). Conclusion given as initial delays

参考文章(10)
Naoto Kamiya, Hiroyoshi Suzuki, Takumi Endo, Makoto Takano, Masashi Yano, Makito Naoi, Daisuke Nishimi, Koji Kawamura, Takashi Imamoto, Tomohiko Ichikawa, Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade International Journal of Urology. ,vol. 19, pp. 169- 173 ,(2012) , 10.1111/J.1442-2042.2011.02914.X
Robert Coleman, Richard Cook, Vera Hirsh, Pierre Major, Allan Lipton, Zoledronic acid use in cancer patients: more than just supportive care? Cancer. ,vol. 117, pp. 11- 23 ,(2011) , 10.1002/CNCR.25529
Masahiro Nozawa, Takeshi Inagaki, Kazuhiro Nagao, Tsukasa Nishioka, Takahiro Komura, Atsunobu Esa, Michio Kitagawa, Masaaki Imanishi, Yasunari Uekado, Takatoshi Ogawa, Hiroshi Kajikawa, Shigeya Uejima, Hideyasu Matsuyama, Isao Hara, Hirotsugu Uemura, Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis International Journal of Clinical Oncology. ,vol. 19, pp. 693- 701 ,(2014) , 10.1007/S10147-013-0604-Z
Allan Lipton, Richard Cook, Fred Saad, Pierre Major, Patrick Garnero, Evangelos Terpos, Janet E. Brown, Robert E. Coleman, Normalization of Bone Markers Is Associated With Improved Survival in Patients With Bone Metastases From Solid Tumors and Elevated Bone Resorption Receiving Zoledronic Acid Cancer. ,vol. 113, pp. 193- 201 ,(2008) , 10.1002/CNCR.23529
Luis Costa, Laurence M Demers, A Gouveia-Oliveira, J Schaller, Eduardo B Costa, Miguel C De Moura, Allan Lipton, Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status Journal of Clinical Oncology. ,vol. 20, pp. 850- 856 ,(2002) , 10.1200/JCO.20.3.850
Fred Saad, Donald M Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner, Louis Lacombe, Joseph L Chin, Jeferson J Vinholes, J Allen Goas, Ming Zheng, None, Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer Journal of the National Cancer Institute. ,vol. 96, pp. 879- 882 ,(2004) , 10.1093/JNCI/DJH141
S. Rajpar, C. Massard, A. Laplanche, E. Tournay, M. Gross-Goupil, Y. Loriot, M. Di Palma, A. Bossi, B. Escudier, A. Chauchereau, K. Fizazi, Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer Annals of Oncology. ,vol. 21, pp. 1864- 1869 ,(2010) , 10.1093/ANNONC/MDQ037
Constantine S Mitsiades, John Bogdanos, Dimitrios Karamanolakis, Constantine Milathianakis, Michael Koutsilieris, Theodoros Dimopoulos, Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Research. ,vol. 26, pp. 3693- 3700 ,(2006)
H. Eidtmann, R. de Boer, N. Bundred, A. Llombart-Cussac, N. Davidson, P. Neven, G. von Minckwitz, J. Miller, N. Schenk, R. Coleman, Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study Annals of Oncology. ,vol. 21, pp. 2188- 2194 ,(2010) , 10.1093/ANNONC/MDQ217
Robert E. Coleman, Pierre Major, Allan Lipton, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, Ming Zheng, Yong Jiang Hei, John Seaman, Richard Cook, Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid Journal of Clinical Oncology. ,vol. 23, pp. 4925- 4935 ,(2005) , 10.1200/JCO.2005.06.091